Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 21, 2026

Johnson & Johnson reports Q4 and Full-Year 2025 results

View original at finance.yahoo.com
Johnson & Johnson reports Q4 and Full-Year 2025 results 2025 Fourth-Quarter reported sales growth of 9.1% to $24.6 Billion with operational growth of 7.1%* and adjusted operational growth of 6.1%*; 2025 Fourth-Quarter earnings per share (EPS) of $2.10 and adjusted EPS of $2.46, both include $(0.10) due to the acquisiti…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2026 adjusted operational EPS guidance of $11.28-$11.48 with midpoint of $11.38 representing 5.5% growth

    80% confidence

  • 2026 adjusted EPS guidance of $11.43-$11.63 with midpoint of $11.53 representing 6.9% growth

    80% confidence

  • TREMFYA is the only IL-23 inhibitor proven to inhibit structural joint damage in active psoriatic arthritis

    80% confidence

  • INLEXZO achieved 74% disease-free survival at one year in BCG-unresponsive high-risk papillary-only NMIBC

    80% confidence

  • DARZALEX FASPRO is the first/only FDA-approved treatment for high-risk smoldering multiple myeloma

    80% confidence

  • 2026 adjusted operational sales growth guidance of 5.4%-6.4% with midpoint of 5.9%

    80% confidence

  • RYBREVANT FASPRO + LAZCLUZE has the shortest administration time for first-line combination regimen

    80% confidence

  • 2026 operational sales guidance of $99.5B-$100.5B with midpoint of $100.0B representing 6.2% growth

    80% confidence

  • TECVAYLI + DARZALEX FASPRO demonstrated superior PFS and OS vs. standard of care in second-line multiple myeloma

    80% confidence

  • Nipocalimab is the first/only investigational FcRn blocker showing potential to reduce SLE activity in Phase 2

    80% confidence

  • AKEEGA demonstrates 54% reduction in disease progression in BRCA2-mutated metastatic castration-sensitive prostate cancer

    80% confidence

  • 2026 reported sales guidance of $100.0B-$101.0B with midpoint of $100.5B representing 6.7% growth

    80% confidence

  • Subcutaneous amivantamab achieved 45% overall response rate with 7.2-month median duration in recurrent/metastatic head and neck cancer

    80% confidence

Cited in these Via News reports

Johnson & Johnson reports Q4 and Full-Year 2025 results — Source | Via News | ViaNews Market